StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Trading Down 0.2 %

Shares of MRNS stock opened at $0.55 on Tuesday. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $9.41. The firm’s 50 day moving average is $0.55 and its 200 day moving average is $0.76. The stock has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $104,000. Virtu Financial LLC bought a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $54,000. JPMorgan Chase & Co. raised its position in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 126,752 shares during the period. Finally, Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $107,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.